1Melton ST,Wood JM,Kirkwood CK.Eszopiclone for insomnia[J].Ann Pharmacotherapy,2005,39:1659-1666.
2Davies M,Glen NJ,Derry JMC,et al.Characterization of the interaction of zopiclone with gamma-aminobutyric acid type A receptor[J].Mol Pharmacol,2000,58:756-762.
3Mikkelsen JD,Soderman A,Kiss A,et al.Effects of benzodiazepines receptor agonists on the hypothalamic-pituitary-adrenocortical axis[J].Eur J Pharmacol,2005,519:223-230.
4Walsh JK.Pharmacologic management of isomnia[J].J Clin Psychiatry,2004,65(Suppl 16):41-45.
5Yasui M,Kato A,Kanemasa T,et al.Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes[J].Nihon Shinkei Seishin Yakurigaku Zasshi,2005,25:143-151.
6Glass J,Lanctot KL,Herrmann N,et al.Sedative hypnotics in older people with insomnia:meta-analysis of risks and benefits[J].BMJ,2005,331:1169-1172.
7Krystal AD,Walsh JK,Laska E,et al.Sustained efficacy of eszopiclone over 6 months of nightly treatment results of a randomized double-blind,placebo-controlled study in adults wiyh chronic insomnia[J].Sleep,2003,26:793-795.
8Rosenberg R,Caron J,Roth T,et al.An assessment of the efficacy and safety of eszopiclone in the treatment of transient insomnia in healthy adults[J].Sleep Med,2005,6:15-22.
9Zammit GK,Mcnabb LJ,Caron J,et al.Efficacy and safety of aszopiclone across 6-week of treatment for primary insomnia[J].Curr Med Res Opin,2004,20:1979-1992.
10Krystal A,Walsh J,Roth T,et al.The sustained efficacy and safety of eszopiclone over six months of nighty treatment:a placebo controlled study in patients with chronic insomnia[J].Sleep,2003,6(suppl 7):779-786.
